直接比较低剂量率近距离放疗与根治性前列腺切除术治疗中危前列腺癌:采用生化复发手术定义
对933例接受种子源近距离放疗(SEED-BT)和334例根治性前列腺切除术(RP)的中危前列腺癌患者进行倾向性评分匹配(214对)。SEED-BT用Phoenix定义、RP用手术定义时,SEED-BT的8年无生化复发率优于RP(87.4% vs 74.3%,HR 0.420,95%CI 0.273-0.647);统一采用手术定义(PSA 0.2 ng/mL)时两组无显著差异(76.7% vs 74.3%,HR 0.913,95%CI 0.621-1.341)。
要点
- 匹配后1:1分析(214对)中,SEED-BT的8年无BCR率优于RP(87.4% vs 74.3%),但统一采用手术定义后差异无统计学意义(76.7% vs 74.3%)。
- SEED-BT组8年免挽救性激素治疗率显著优于RP(92.0% vs 85.6%,HR 0.528,95%CI 0.296-0.942,P=0.030)。
- 两组8年无转移生存率(98.5% vs 99.0%,HR 1.382,95%CI 0.313-6.083,P=0.668)和总生存率(91.9% vs 94.6%,HR 1.353,95%CI 0.690-2.650)无显著差异。
核心结论
- 对于中危前列腺癌患者,即使直接采用手术定义(PSA 0.2 ng/mL)比较,SEED-BT与RP的无生化复发率也无显著差异。
研究设计与样本
- 倾向性评分1:1匹配的回顾性比较研究,纳入接受SEED-BT(n=933)或RP(n=334)的中危前列腺癌患者,匹配后214对。
- SEED-BT组采用Phoenix定义(PSA最低值+2 ng/mL)判定生化复发,RP组采用手术定义(PSA截止值0.2 ng/mL)判定。
- 同时对两种治疗统一采用PSA 0.2 ng/mL的截止值直接比较无生化复发率。
主要发现
- 匹配后中位随访96个月(范围1-158个月);SEED-BT组中53例(24.7%)接受近距离放疗联合外照射放疗,RP组中43例(20.0%)接受术后挽救性放疗。
- SEED-BT组8年无生化复发率显著优于RP组(87.4% vs 74.3%,HR 0.420,95%CI 0.273-0.647)。
- 统一采用手术定义时,两组8年无生化复发率无显著差异(76.7% vs 74.3%,HR 0.913,95%CI 0.621-1.341)。
- SEED-BT组8年免挽救性激素治疗率显著优于RP组(92.0% vs 85.6%,HR 0.528,95%CI 0.296-0.942,P=0.030)。
- 两组8年无转移生存率(98.5% vs 99.0%,HR 1.382,95%CI 0.313-6.083,P=0.668)和总生存率(91.9% vs 94.6%,HR 1.353,95%CI 0.690-2.650)无显著差异。
临床怎么用
- 作者认为,即使直接采用手术定义判定生化复发,SEED-BT与RP治疗中危前列腺癌的肿瘤学结局也可进行充分比较。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We compared the oncological outcomes of patients who received seed brachytherapy (SEED-BT) with those who received radical prostatectomy (RP) for intermediate-risk prostate cancer. METHODS: Candidates were patients treated with either SEED-BT (n = 933) or RP (n = 334). One-to-one propensity score matching was performed to adjust the patients' backgrounds. We compared the biochemical recurrence (BCR)-free rate using the Phoenix definition (prostate-specific antigen [PSA] nadir plus 2 ng/mL) for SEED-BT and the surgical definition (PSA cut-off value of 0.2 ng/mL) for RP. We also directly compared the BCR-free rates using the same PSA cut-off value of 0.2 ng/mL for both SEED-BT and RP. RESULTS: In the propensity score-matched analysis with 214 pairs, the median follow-up treatment was 96 months (range 1-158 months). Fifty-three patients (24.7%) were treated with combined SEED-BT and external-beam radiotherapy. Forty-three patients (20.0%) received salvage radiotherapy after RP. Comparing the BCR-free rate using the above definitions for SEED-BT and RP showed that SEED-BT yielded a significantly better 8-year BCR-free rate than did RP (87.4% vs. 74.3%, hazard ratio [HR] 0.420, 95% confidence interval [CI] 0.273-0.647). Comparing the 8-year BCR-free rate using the surgical definition for both treatments showed no significant difference between the two treatments (76.7% vs. 74.3%, HR 0.913, 95% CI 0.621-1.341). SEED-BT had a significantly better 8-year salvage hormonal therapy-free rate than did RP (92.0% vs. 85.6%, HR 0.528, 95% CI 0.296-0.942, P = 0.030). The 8-year metastasis-free survival rates (98.5% vs. 99.0%, HR 1.382, 95% CI 0.313-6.083, P = 0.668) and overall survival rates (91.9% vs. 94.6%, HR 1.353, 95% CI 0.690-2.650) did not significantly differ between the treatments. CONCLUSIONS: The BCR-free rates did not significantly differ between patients treated with SEED-BT and those treated with RP for intermediate-risk prostate cancer even when they were directly compared using the surgical definition for BCR. SEED-BT and RP can be adequately compared for oncological outcomes.
引用
- Tsumura H, Tanaka N, Oguchi T, et al. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiat Oncol. 2022. PMID: 35410307. doi:10.1186/s13014-022-02046-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。